AbbVie, a research-based global biopharmaceutical company, announced it will present data from multiple studies of Rinvoq (upadacitinib), Humira (adalimumab) and Skyrizi (risankizumab) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, November 8-13, in Atlanta. A total of 38 abstracts will be presented across multiple rheumatic conditions, including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
“AbbVie looks forward to sharing the latest research across our recently expanded rheumatology portfolio at this year’s meeting, including data that further support our recent FDA approval of Rinvoq,” said Marek Honczarenko, M.D., Ph.D., vice president, global immunology development, AbbVie. “New data being presented on upadacitinib, risankizumab and adalimumab across multiple rheumatic diseases will highlight the potential for all three treatment options to help more patients achieve their treatment goals.”
For the first time, safety and efficacy data evaluating upadacitinib versus placebo for the treatment of signs and symptoms in patients with active AS who had an inadequate response to nonsteroidal anti-inflammatory drugs will be presented during a plenary session at the meeting.
A number of upadacitinib RA abstracts will also be featured, including: Investigators will present clinical remission data in patients treated with upadacitinib compared to placebo and methotrexate. Long-term data from the SELECT program will be presented evaluating the efficacy and safety of upadacitinib across clinical measures and patient reported outcomes. Investigators will share data evaluating upadacitinib compared to adalimumab across clinical and functional responses. Data will also be presented among patients who experience an initial insufficient response to either upadacitinib or adalimumab and switched to the other therapy
Investigators will also present new patient-reported outcomes in patients with moderate to severe PsA who were treated with adalimumab, as well as data evaluating the safety and efficacy of risankizumab in patients with active PsA.
Rheumatic diseases affect patients’ joints, tendons, ligaments, bones and muscles. Early diagnosis and intervention with an effective treatment is critical to controlling rheumatic diseases and preventing permanent damage.
Discovered and developed by AbbVie, Rinvoq is an oral JAK inhibitor approved by the US Food and Drug Administration (FDA) and under review with health authorities globally for the treatment of moderately to severely active rheumatoid arthritis and being studied in other immune-mediated inflammatory diseases. Earlier this year, Rinvoq received US Food and Drug Administration approval for patients with moderately to severely active rheumatoid arthritis. Rinvoq also received a positive opinion from the Committee for Medicinal Products for Human Use and is currently in European Union regulatory review for patients with moderately to severely active rheumatoid arthritis. Phase 3 trials of Rinvoq in psoriatic arthritis, Crohn’s disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing and it is also being investigated to treat ankylosing spondylitis.
Skyrizi is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis.
Skyrizi is approved in the US, European Union and Canada for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.
Phase 3 trials of Skyrizi in Crohn’s disease and psoriatic arthritis are ongoing, and it is also being investigated to treat ulcerative colitis.-Pharma Biz